OXONIC ACID POTASSIUM SALT CAS 2207-75-2

It is one of the key components of the anti-cancer drug S-1. S-1 is an oral fluorouracil antitumor drug composed of Tegafur, Gimeracil, and potassium oxonate in a molar ratio of 1:0.4:1. Tigafur is a prodrug of 5-fluorouracil (5-FU), which exerts anti-tumor effects after being converted into 5-FU in vivo; Jimeipyrimidine slows down the catabolism of 5-FU by inhibiting the activity of dihydropyrimidine dehydrogenase (DPD), thereby prolonging its effective concentration in the body; As a uricase inhibitor, it significantly reduces the toxicity of 5-FU to gastrointestinal mucosa by inhibiting its phosphorylation to 5-fluorouridine-5 '- mnophosphate (FUMP) in the gastrointestinal tract, without weakening its anti-tumor activity.

This characteristic makes S-1 widely used in the treatment of solid tumors such as gastric cancer, pancreatic cancer, lung cancer, head and neck cancer and breast cancer. For example, in adjuvant chemotherapy for gastric cancer, S-1 monotherapy or combination with other drugs (such as cisplatin) can significantly improve the survival rate and quality of life of patients. Compared with the traditional 5-FU intravenous infusion regimen, S-1 oral administration is convenient and has better patient tolerance, especially suitable for elderly patients or patients with poor physical condition.

It is an effective uricase inhibitor that can block the metabolism and excretion pathways of uric acid. In experimental animals such as rats and mice, potassium oxonate can be induced to develop hyperuricemia through intraperitoneal injection or oral administration. Its mechanism of action is to inhibit the activity of uricase in the liver and kidneys, reduce the breakdown of uric acid into allantoin, and inhibit the reabsorption of uric acid by renal tubules, leading to an increase in blood uric acid levels.

This characteristic makes potassium oxonate an important tool for studying the pathogenesis of diseases such as gout and metabolic syndrome. By constructing a high uric acid animal model, researchers can delve into the relationship between abnormal uric acid metabolism and pathological processes such as inflammation, oxidative stress, and insulin resistance, providing reliable experimental evidence for the development of new uric acid lowering drugs. For example, using a hyperuricemia rat model induced by potassium oxonate, researchers have found that certain traditional Chinese medicine extracts or natural compounds (such as baicalin and quercetin) have significant uric acid lowering and anti-inflammatory effects, providing new candidate drugs for the treatment of gout.

Oxonic acid potassium salt also shows a certain protective effect in the cardiovascular system. Research has shown that potassium oxonate can promote the synthesis and release of nitric oxide (NO) in endothelial cells, dilate blood vessels, and lower blood pressure. NO is an important vasodilator that can inhibit platelet aggregation and leukocyte adhesion, reducing vascular inflammatory responses. In addition, it can also slow down the occurrence and development of atherosclerosis by reducing the production of free radicals, inhibiting oxidative stress reaction, and protecting vascular endothelial cells from damage.

In animal experiments, pretreatment can significantly alleviate myocardial ischemia-reperfusion injury, reduce myocardial infarction area, and improve cardiac function. The mechanism may be related to inhibiting inflammatory response, reducing cell apoptosis, and promoting angiogenesis. These findings provide a theoretical basis for the application of potassium oxonate in the prevention and treatment of cardiovascular diseases, but further clinical research is needed to verify its safety and effectiveness.

The anti-inflammatory properties of potassium oxonate make it potentially valuable for the treatment of respiratory diseases. Asthma and chronic obstructive pulmonary disease (COPD) are two common chronic respiratory diseases, and their pathogenesis is closely related to airway inflammation, oxidative stress, and immune imbalance. It can alleviate airway inflammation by inhibiting the activation of inflammatory cells (such as macrophages and neutrophils) and the release of inflammatory factors (such as tumor necrosis factor - α and interleukin-6).

In addition, by regulating the immune response, airway hyperresponsiveness can be reduced, and symptoms of asthma and COPD patients can be alleviated. In animal models, potassium oxonate pretreatment can significantly alleviate allergen induced airway inflammation and remodeling, and improve lung function. These research findings suggest that it may become a novel therapeutic drug for respiratory diseases, but further clinical trials are needed to evaluate its efficacy and safety.

Preliminary research suggests that it also has a certain protective effect on the nervous system. In ischemic brain injury models, pre-treatment can reduce the volume of cerebral infarction and improve neurological deficits. The mechanism may be related to inhibiting inflammatory response, reducing the expression of oxidative stress and apoptosis related proteins. In addition, promoting the synthesis and release of nerve growth factors can also facilitate the survival and regeneration of nerve cells, providing new ideas for the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

For example, using potassium oxazinate to treat cells or animal models, researchers found that high uric acid environment can induce endothelial cell dysfunction, promote the proliferation and migration of vascular smooth muscle cells, and accelerate the occurrence of atherosclerosis. In addition, oxonic acid potassium salt can also be used to study the interaction between uric acid and oxidative stress, inflammatory response, providing important clues for revealing the pathogenesis of metabolic diseases.

In the development of anti-tumor drugs, reducing the gastrointestinal toxicity of 5-FU provides an ideal animal model for evaluating the efficacy and safety of new chemotherapy drugs. The traditional 5-FU intravenous infusion regimen often leads to severe gastrointestinal reactions such as nausea, vomiting, and diarrhea, limiting its clinical application. S-1, containing potassium oxonate, can significantly reduce these side effects and improve patient tolerance.

By using the animal model constructed, researchers can compare the anti-tumor effects and toxic reactions of different chemotherapy regimens (such as S-1 monotherapy or S-1 in combination with other drugs), and optimize treatment plans. In addition, it can also be used to study drug pharmacokinetics and pharmacodynamics, providing important experimental basis for new drug development.

The induced hyperuricemia animal model provides a powerful tool for studying the interaction between uric acid and metabolic syndrome components such as obesity, diabetes, hypertension, etc. Metabolic syndrome is a clinical syndrome with insulin resistance as its core, accompanied by various metabolic abnormalities such as hypertension, hyperglycemia, dyslipidemia, and obesity. Its pathogenesis is complex and involves multiple factors.

By using it to build an animal model of hyperuricemia, researchers found that hyperuricemia can induce insulin resistance, promote adipose tissue inflammation and adipocyte differentiation, increase liver fat synthesis, and thus lead to obesity and diabetes. In addition, hyperuricemia can also increase hypertension and accelerate the progression of atherosclerosis by activating renin angiotensin system (RAS) and oxidative stress reaction. These research findings provide a new perspective for a deeper understanding of the pathogenesis of metabolic syndrome and a theoretical basis for developing multi-target intervention strategies.